Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Erstveröffentlichung
2016Authors
du Bois, Andreas
Kristensen, Gunnar
Ray-Coquard, Isabelle
Reuss, Alexander
Pignata, Sandro
Wissenschaftlicher Artikel
Published in
Lancet Oncology ; 17 (2016), 1. - S. 78-89. - ISSN 1470-2045. - eISSN 1474-5488